20.82
1.07%
0.22
Dopo l'orario di chiusura:
20.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$20.60
Aprire:
$20.76
Volume 24 ore:
916.99K
Relative Volume:
1.00
Capitalizzazione di mercato:
$2.48B
Reddito:
$434.48M
Utile/perdita netta:
$68.15M
Rapporto P/E:
20.61
EPS:
1.01
Flusso di cassa netto:
$114.96M
1 W Prestazione:
-11.22%
1M Prestazione:
-1.98%
6M Prestazione:
+26.26%
1 anno Prestazione:
+50.76%
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Confronta CPRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
CPRX | 20.82 | 2.48B | 434.48M | 68.15M | 114.96M | 1.01 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-03-14 | Iniziato | Citigroup | Buy |
2024-03-07 | Iniziato | BofA Securities | Buy |
2023-12-21 | Iniziato | Oppenheimer | Outperform |
2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
2018-09-07 | Ripresa | Piper Jaffray | Overweight |
2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
2014-09-30 | Reiterato | ROTH Capital | Buy |
2014-09-16 | Reiterato | ROTH Capital | Buy |
2014-09-15 | Reiterato | H.C. Wainwright | Buy |
2013-10-21 | Reiterato | Aegis Capital | Buy |
2013-09-24 | Iniziato | Maxim Group | Buy |
2013-09-06 | Reiterato | Aegis Capital | Buy |
2013-04-18 | Iniziato | Aegis Capital | Buy |
2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat
Principal Financial Group Inc. Has $11.45 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga
Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - GlobeNewswire
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance
Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat
CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals' (CPRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Q3 2024 Earnings - TipRanks
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance - Investing.com
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 - Marketscreener.com
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance By Investing.com - Investing.com Canada
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings - Simply Wall St
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides - The Bakersfield Californian
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Prev - GuruFocus.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Catalyst Pharmaceuticals Q3 2024 Earnings Preview - MSN
Catalyst Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
A Peek at Catalyst Pharmaceuticals's Future Earnings - Benzinga
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
DekaBank Deutsche Girozentrale Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Zacks.com featured highlights include Vertiv, Limbach, Atour Lifestyle and Catalyst Pharmaceuticals - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Boosted by Allspring Global Investments Holdings LLC - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month HighHere's Why - MarketBeat
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):